AnaptysBio-Tesaro trial heads to post-trial briefs, argument set for Oct. 20

• AnaptysBio disclosed post-trial briefing dates in its Delaware Chancery Court dispute with Tesaro and parent GlaxoSmithKline over a collaboration license.
• The company seeks a declaration that Tesaro materially breached the agreement, alleging GlaxoSmithKline tortiously interfered.
• The consolidated trial ran July 14-17, 2026; opening brief due Aug. 21, defense brief due Sept. 25, reply due Oct. 9.
• Post-trial argument is scheduled for Oct. 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-326097), on July 30, 2026, and is solely responsible for the information contained therein.